Roche publishes new sclerosis data to keep Novartis at bay
With the recently approved sclerosis treatment, Kesimpta, first developed by Genmab, Novatis is in full swing competing with Roche's dominant medicine on the market. Now Roche attempts retaliation.
by ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINEE JANE BRETT
New data on the use of Roche’s MS treatment Ocrevus in the early stages of the illness will give it a new boost, writes sector media Fiercepharma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA grants new Genmab drug priority review status
For subscribers
Genmab drug becomes more accessible in the US
For subscribers
